CanadaALECENSARO (alectinib) capsules, 150 mg, are the product referenced and can be identified by the product name ALECENSARO and the 150 mg capsule strength. Hypertriglyceridemia, including severe and life‑threatening events, has been identified as an adverse reaction associated with ALECENSARO; severe hypertriglyceridemia may lead to acute pancreatitis.
How to identify it
ALECENSARO, alectinib capsules, 150 mg
The hazard
Hypertriglyceridemia, including severe and life-threatening events, has been identified as an adverse reaction associated with ALECENSARO. Severe hypertriglyceridemia is considered a medical emergency, as it may lead to acute pancreatitis.
What to do
See Key Messages below
The official notice
This page is a summary of the notice published by Health Canada, collected from Health Canada, CFIA and Transport Canada. Check the original before you act on it.
Read the official notice (opens in a new tab)